Eucrates Biomedical Acquisition Corp. Unit

9.9800.00Vol 10.10K1Y Perf -0.20%
Apr 20th, 2021 12:38 DELAYED
BID9.98 ASK10.12
Open9.99 Previous Close9.98
Pre-Market- After-Market-
 - -  - -%
Target Price
- 
Analyst Rating
— — 0.00
Potential %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap- 
Earnings Rating
Price Range Ratio 52W %
6.30 
Earnings Date
-

Today's Price Range

9.989.99

52W Range

9.9011.17

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
0.40%
1 Month
-3.76%
3 Months
-5.44%
6 Months
-
1 Year
-0.20%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
EUCRU9.980.00000.00
AAPL133.11-1.7300-1.28
GOOG2 293.63-8.7700-0.38
MSFT258.26-0.4800-0.19
XOM55.29-1.1900-2.11
WFC42.54-1.3400-3.05
JNJ166.483.79002.33
FB302.650.41000.14
GE13.06-0.4000-2.97
JPM149.27-3.3800-2.21
Earnings HistoryEstimateReportedSurprise %
----
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume10.10K
Shares Outstanding0
Trades Count33
Dollar Volume315.62K
Avg. Volume28.58K
Avg. Weekly Volume14.86K
Avg. Monthly Volume18.35K
Avg. Quarterly Volume31.38K

Eucrates Biomedical Acquisition Corp. Unit (NASDAQ: EUCRU) stock closed at 9.98 per share at the end of the most recent trading day (a 0% change compared to the prior day closing price) with a volume of 10.10K shares and market capitalization of 0.0000. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Diversified Financial Services industry, Financial Services sector and employs 4 people. Eucrates Biomedical Acquisition Corp. Unit CEO is Parag Saxena.

The one-year performance of Eucrates Biomedical Acquisition Corp. Unit stock is -0.2%, while year-to-date (YTD) performance is -6.38%. EUCRU stock has a five-year performance of %. Its 52-week range is between 9.9 and 11.17, which gives EUCRU stock a 52-week price range ratio of 6.30%

Eucrates Biomedical Acquisition Corp. Unit currently has a PE ratio of -, a price-to-book (PB) ratio of -, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -0.14%, a ROC of -% and a ROE of -0.14%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Eucrates Biomedical Acquisition Corp. Unit, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Eucrates Biomedical Acquisition Corp. Unit’s next earnings report date is -.

The consensus rating of Wall Street analysts for Eucrates Biomedical Acquisition Corp. Unit is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Eucrates Biomedical Acquisition Corp. Unit stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Eucrates Biomedical Acquisition Corp. Unit has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Eucrates Biomedical Acquisition Corp. Unit has a Sell technical analysis rating based on Technical Indicators (ADX : 30.85, ATR14 : 0.09, CCI20 : -68.34, Chaikin Money Flow : 0.11, MACD : -0.17, Money Flow Index : 46.07, ROC : -0.30, RSI : 40.22, STOCH (14,3) : 16.22, STOCH RSI : 0.77, UO : 34.89, Williams %R : -83.78), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Eucrates Biomedical Acquisition Corp. Unit in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Eucrates Biomedical Acquisition Corp. Unit

Eucrates Biomedical Acquisition Corp is a blank check company.

CEO: Parag Saxena

Telephone: +1 212 710-5220

Address: 250 West 55th Street, New York 10019, NY, US

Number of employees: 4

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

50%50%

News

Stocktwits